Athersys (NASDAQ: ATHX) is developing MultiStem®, a patented, adult-derived “off-the-shelf” stem cell product platform, for multiple disease indications in the areas of neurological, cardiovascular disease, inflammatory and immune disease, as well as other areas. The company currently has several clinical stage programs and a portfolio of preclinical programs that we are advancing toward clinical stage development.

Funding: Aspire Capital, Radius Ventures, Orbimed, MPM, Hambrecht & Quist, A.M. Pappas Ventures, RA Capital Management, Accipiter Capital, Angiotech, Blue Chip, Invesco, Primus, Western Technology, Piper Jaffray & Co., William Blair & Company, First Analysis, Senmed Medical Ventures, Biotechnology Value Fund Partners, Van Wagoner Capital, NEOMed Management, Cogene Ventures, Crestwood Capital Partners, DRW Venture Partners

Stage: Clinical

News: Athersys and Healios Complete Deal to Expand their MultiStem Partnership